J Infect Dis: Statins can reduce the 28-day mortality of hospitalized patients with new crown infection

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) caused by the new crown epidemic ( COVID-19 ) has caused millions of deaths around the world.
In the early stage, more than 100 kinds of drugs were used for treatment New crown
.

Among them, statins are also used in the treatment of new coronary disease due to their cardioprotective effects, and they can also weaken the excessive inflammatory response caused by infection .

Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) caused by the new crown epidemic ( COVID-19 ) has caused millions of deaths around the world.

 

Researchers divided the patients into 4 groups based on their use of statins: patients who used statins before hospitalization (continued use group, discontinuation group) and those who had never used it (newly initiated group, never group)
.

Then, in a cohort study of 1179 SARS-CoV-2 patients, the demographics, laboratory indicators, comorbidities, and the time from admission to death, admission to the ICU or discharge from the hospital were all counted

 

Of the 1179 patients, 676 (57%) were male, 443 (37%) were older than 65 years, and 493 (46%) had a BMI ≥ 30
.

The use of statins in hospitalized patients reduced the risk of death (HR 0.

 

This study confirmed that the use of statins during hospitalization due to SARS-CoV-2 infection is associated with a 28-day mortality reduction.
The off-label use of statins is currently proven to be safe and effective
.

This study confirmed that the use of statins during hospitalization due to SARS-CoV-2 infection is associated with a 28-day mortality reduction.
The off-label use of statins is currently proven to be safe and effective
.

 

 

Original source:

Zoe N Memel.

Association of Statins and 28-Day Mortality in Patients Hospitalized with SARS CoV-2 Infection.
Leave a message here